**Author details**

Paula Parreira1,2, Catarina Leal Seabra1,2, Daniela Lopes-de-Campos<sup>3</sup> and Maria Cristina L. Martins1,2,4\*

\*Address all correspondence to: cmartins@ineb.up.pt


#### **References**


[6] Piazuelo MB, Epplein M, Correa P. Gastric cancer: An infectious disease. Infectious Disease Clinics of North America. 2010;**24**(4):853-869

**Acknowledgements**

CTM-BIO/4043/2014).

**Conflict of interest**

**Author details**

**References**

**133**(2):659-672

factsheets/fs297/en/

Microbiology. 2016;**42**(1):94-105

2017;**2017**:1-71

Maria Cristina L. Martins1,2,4\*

The authors declare no conflict of interest.

118 Helicobacter Pylori - New Approaches of an Old Human Microorganism

Paula Parreira1,2, Catarina Leal Seabra1,2, Daniela Lopes-de-Campos<sup>3</sup>

\*Address all correspondence to: cmartins@ineb.up.pt

The authors acknowledge FEDER—Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020—Operational Program for Competitiveness and Internationalization (POCI), Portugal 2020, NORTE-01-0145-FEDER-000012, and PyloriBinders—*Helicobacter pylori*-specific biomaterials for antibiotic-free treatment/diagnostic of gastric infection (PTDC/

1 i3S—Instituto de Investigação e Inovação em Saúde, University of Porto, Porto, Portugal

4 ICBAS—Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Portugal

[1] Correa P, Houghton J. Carcinogenesis of *Helicobacter pylori*. Gastroenterology. 2007;

[2] Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase. No. 11 [Internet]. Vol. 11. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.f [3] WHO. WHO Cancer. WHO. 2017. Available from: http://www.who.int/mediacentre/

[4] American Cancer Society. Cancer facts & figures 2017. American Cancer Society Journal.

[5] Parreira P, Fátima Duarte M, Reis CA, Martins MCL. *Helicobacter pylori* infection: A brief overview on alternative natural treatments to conventional therapy. Critical Reviews in

2 INEB—Instituto de Engenharia Biomédica, University of Porto, Porto, Portugal 3 LAQV, REQUIMTE, Faculty of Pharmacy, University of Porto, Porto, Portugal

and


[21] Altiok D, Altiok E, Bayraktar O, Tihminlioglu F. Stability of trans-resveratrol incorporated in chitosan microspheres. In: 14th Natl Biomed Eng Meet. 2009

[35] Chow CK. Fatty Acids in Foods and their Health Implications. 3rd ed. Boca Raton, FL:

Nonantibiotic-Based Therapeutics Targeting *Helicobacter pylori*: From Nature to the Lab

http://dx.doi.org/10.5772/intechopen.81248

[36] Desbois AP, Smith VJ. Antibacterial free fatty acids: Activities, mechanisms of action and biotechnological potential. Applied Microbiology and Biotechnology. 2010;**85**(6):

[37] Desbois AP. Potential applications of antimicrobial fatty acids in medicine, agriculture and other industries. Recent Patents on Anti-Infective Drug Discovery. 2012;**7**(2):111-122

[38] Yoon B, Jackman J, Valle-González E, Cho N-J. Antibacterial free fatty acids and monoglycerides: Biological activities, experimental testing, and therapeutic applications.

[39] Calder PC. Mechanisms of action of (n-3) fatty acids. The Journal of Nutrition. 2012;**142**(3):

[40] Sun CQ, O'Connor CJ, Roberton AM. Antibacterial actions of fatty acids and monoglycerides against *Helicobacter pylori*. FEMS Immunology and Medical Microbiology.

[41] Khulusi S, Ahmed HA, Patel P, Mendall MA, Northfield TC. The effects of unsaturated fatty acids on *Helicobacter pylori in vitro*. Journal of Medical Microbiology.

[42] Correia M, Michel V, Matos AA, Carvalho P, Oliveira MJ, Ferreira RM, et al. Docosahexaenoic acid inhibits helicobacter pylori growth in vitro and mice gastric

[43] Correia M, Michel V, Osorio H, El Ghachi M, Bonis M, Boneca IG, et al. Crosstalk between *Helicobacter pylori* and gastric epithelial cells is impaired by docosahexaenoic acid. PLoS

[44] Seabra CL, Nunes C, Brás M, Gomez-Lazaro M, Reis CA, Gonçalves IC, et al. Lipid nanoparticles to counteract gastric infection without affecting gut microbiota. European

[45] Thompson L, Cockayne A, Spiller RC. Inhibitory effect of polyunsaturated fatty acids on the growth of *Helicobacter pylori*: A possible explanation of the effect of diet on peptic

[46] Bazinet RP, Laye S. Polyunsaturated fatty acids and their metabolites in brain function

[47] Catal A. Five decades with polyunsaturated fatty acids: Chemical synthesis, enzymatic formation, lipid peroxidation and its biological effects. Journal of Lipids. 2013;**2013**:19

[48] Correia M, Casal S, Vinagre J, Seruca R, Figueiredo C, Touati E, et al. *Helicobacter pylori*'s cholesterol uptake impacts resistance to docosahexaenoic acid. International Journal of

Journal of Pharmaceutics and Biopharmaceutics. 2018;**127**:378-386

and disease. Nature Reviews. Neuroscience. 2014;**15**(12):771-785

International Journal of Molecular Sciences. 2018;**19**(4):1114

mucosa colonization. PLoS One. 2012;**7**(4):e35072

CRC Press: Taylor & Francis Group; 2008

1629-1642

592S-599S

2003;**36**:9-17

1995;**42**(4):276-282

One. 2013;**8**(4):e60657

ulceration. Gut. 1994;**35**:1557-1561

Medical Microbiology. 2014;**304**(3-4):314-320


[35] Chow CK. Fatty Acids in Foods and their Health Implications. 3rd ed. Boca Raton, FL: CRC Press: Taylor & Francis Group; 2008

[21] Altiok D, Altiok E, Bayraktar O, Tihminlioglu F. Stability of trans-resveratrol incorpo-

[22] Zhang XL, Jiang AM, Ma ZY, Li XB, Xiong YY, Dou JF, et al. The synthetic antimicrobial peptide pexiganan and its nanoparticles (PNPs) exhibit the anti-*Helicobacter pylori* activ-

[23] Chang C-H, Huang W-Y, Lai C-H, Hsu Y-M, Yao Y-H, Chen T-Y, et al. Development of novel nanoparticles shelled with heparin for berberine delivery to treat *Helicobacter* 

[24] Cláudio AFM, Neves MC, Shimizu K, Canongia Lopes JN, Freire MG, Coutinho JAP. The magic of aqueous solutions of ionic liquids: Ionic liquids as a powerful class of catan-

[25] Domínguez de María P, Maugeri Z. Ionic liquids in biotransformations: From proofof-concept to emerging deep-eutectic-solvents. Current Opinion in Chemical Biology.

[26] Ressmann AK, Strassl K, Gaertner P, Zhao B, Greiner L, Bica K. New aspects for biomass processing with ionic liquids: Towards the isolation of pharmaceutically active betulin.

[27] Battaglia L, Gallarate M. Lipid nanoparticles: State of the art, new preparation methods and challenges in drug delivery. Expert Opinion on Drug Delivery. 2012;**9**(5):497-508

[28] Carbone C, Leonardi A, Cupri S, Puglisi G, Pignatello R. Pharmaceutical and biomedical applications of lipid-based nanocarriers. Journal of Pharmaceutical and Biomedical

[29] Takahashi M, Kitamoto D, Imura T, Oku H, Takara K, Wada K. Characterization and bioavailability of liposomes containing a ukon extract. Bioscience, Biotechnology, and

[30] Thamphiwatana S, Fu V, Zhu J, Lu D, Gao W, Zhang L. Nanoparticle-stabilized liposomes for ph-responsive gastric drug delivery. Langmuir. 2013;**29**(39):12228-12233 [31] Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical

[32] Seabra CL, Nunes C, Gomez-Lazaro M, Correia M, Machado JC, Gonçalves IC, et al. Docosahexaenoic acid loaded lipid nanoparticles with bactericidal activity against

[33] Dolatabadi JEN, Valizadeh H, Hamishehkar H. Solid lipid nanoparticles as efficient drug and gene delivery systems: Recent breakthroughs. Advanced Pharmaceutical Bulletin.

[34] Jackman JA, Yoon BK, Li D, Cho NJ. Nanotechnology formulations for antibacterial free

*Helicobacter pylori*. International Journal of Pharmaceutics. 2017;**519**(1-2):128-137

rated in chitosan microspheres. In: 14th Natl Biomed Eng Meet. 2009

ity *in vitro* and *in vivo*. Molecules. 2015;**20**(3):3972-3985

ionic hydrotropes. Green Chemistry. 2015;**17**(7):3948-3963

*pylori*. Acta Biomaterialia. 2011;**7**(2):593-603

120 Helicobacter Pylori - New Approaches of an Old Human Microorganism

2011;**15**(2):220-225

Green Chemistry. 2012;**14**(4):940

Analysis. 2014;**3**(2):199-215

2015;**5**(2):151-159

Biochemistry. 2008;**72**(5):1199-1205

use: An updated review. Pharmaceutics. 2017;**27**(9):2

fatty acids and monoglycerides. Molecules. 2016;**21**(3):305


[49] Park S-H, Kangwan N, Park J-M, Kim E-H, Hahm KB. Non-microbial approach for *Helicobacter pylori* as faster track to prevent gastric cancer than simple eradication. World Journal of Gastroenterology. 2013;**19**(47):8986-8995

[63] Wang G, Tang W, Bidigare RR. Terpenoids as therapeutic drugs and pharmaceutical agents. In: Zhang L, Demain A, editors. Natural Products Drug Discovery and

Nonantibiotic-Based Therapeutics Targeting *Helicobacter pylori*: From Nature to the Lab

http://dx.doi.org/10.5772/intechopen.81248

[64] Jäger S, Trojan H, Kopp T, Laszczyk MN, Scheffler A. Pentacyclic triterpene distribution in various plants—Rich sources for a new group of multi-potent plant extracts.

[65] Sheng H, Sun H. Synthesis, biology and clinical significance of pentacyclic triterpenes: A multi-target approach to prevention and treatment of metabolic and vascular diseases.

[66] Furtado NAJC, Pirson L, Edelberg H, Miranda LM, Loira-Pastoriza C, Preat V, et al. Pentacyclic triterpene bioavailability: An overview of *in vitro* and *in vivo* studies.

[67] Paraschos S, Magiatis P, Mitakou S, Petraki K, Kalliaropoulos A, Maragkoudakis P, et al. *In vitro* and *in vivo* activities of chios mastic gum extracts and constituents against

[68] Shin S-J, Park C-E, Baek N-I, Chung IS, Park C-H. Betulinic and oleanolic acids isolated from *Forsythia suspensa* Vahl inhibit urease activity of *Helicobacter pylori*. Biotechnology

[69] Parreira P, Soares BIG, Freire CSR, Silvestre AJD, Reis CA, Martins MCL, et al. *Eucalyptus* spp. outer bark extracts inhibit *Helicobacter pylori* growth: *In vitro* studies. Industrial

[70] Jiang Q, Yang X, Du P, Zhang H, Zhang T. Dual strategies to improve oral bioavailability of oleanolic acid: Enhancing water-solubility, permeability and inhibiting cytochrome P450 isozymes. European Journal of Pharmaceutics and Biopharmaceutics. 2016;**99**:65-72

[71] Yang G, Yang T, Zhang W, Lu M, Ma X, Xiang G. *In vitro* and *in vivo* antitumor effects of folate-targeted ursolic acid stealth liposome. Journal of Agricultural and Food

[72] Ge ZQ, Du XY, Huang XN, Qiao B. Enhanced oral bioavailability of ursolic acid nanoparticles via antisolvent precipitation with TPGS1000 as a stabilizer. Journal of

[73] Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. Perspectives in

[74] Miller LH, Su X. Artemisinin: Discovery from the Chinese herbal garden. Cell. 2011;**146**(6):

*Helicobacter pylori*. Antimicrobial Agents and Chemotherapy. 2007;**51**(2):551-559

Therapeutic Medicine. Totowa, NJ: Humana Press; 2005. pp. 197-227

Molecules (Basel, Switzerland). 2009;**14**:2016-2031

and Bioprocess Engineering. 2009;**14**(2):140-145

Drug Delivery Science and Technology. 2015;**29**:210-217

Crops and Products. 2017;**105**:207-214

Chemistry. 2014;**62**(10):2207-2215

Medicinal Chemistry. 2014;**6**:25-64

855-858

Natural Product Reports. 2011;**28**(3):543

Molecules. 2017;**22**(3):400


[63] Wang G, Tang W, Bidigare RR. Terpenoids as therapeutic drugs and pharmaceutical agents. In: Zhang L, Demain A, editors. Natural Products Drug Discovery and Therapeutic Medicine. Totowa, NJ: Humana Press; 2005. pp. 197-227

[49] Park S-H, Kangwan N, Park J-M, Kim E-H, Hahm KB. Non-microbial approach for *Helicobacter pylori* as faster track to prevent gastric cancer than simple eradication. World

[50] Park J-M, Jeong M, Kim E-H, Han Y-M, Kwon SH, Hahm K-B. Omega-3 polyunsaturated fatty acids intake to regulate *Helicobacter pylori*-associated gastric diseases as nonantimi-

[51] Dyall SC. Methodological issues and inconsistencies in the field of omega-3 fatty acids research. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2011;**85**(5):281-285 [52] Hadian Z. A review of nanoliposomal delivery system for stabilization of bioactive

[53] Thamphiwatana S, Gao W, Obonyo M, Zhang L. *In vivo* treatment of *Helicobacter pylori* infection with liposomal linolenic acid reduces colonization and ameliorates inflammation. Proceedings of the National Academy of Sciences of the United States of America.

[54] Yashodhara BM, Umakanth S, Pappachan JM, Bhat SK, Kamath R, Choo BH. Omega-3 fatty acids: A comprehensive review of their role in health and disease. Postgraduate

[55] Das UN. Essential fatty acids—A review. Current Pharmaceutical Biotechnology.

[56] Manjari V, Das UN. Oxidant stress, anti-oxidants, nitric oxide and essential fatty acids in peptic ulcer disease. Prostaglandins, Leukotrienes and Essential Fatty Acids.

[57] Obonyo M, Zhang L, Thamphiwatana S, Pornpattananangkul D, Fu V, Zhang L. Antibacterial activities of liposomal linolenic acids against antibiotic-resistant *Helicobacter* 

[58] Jung SW, Thamphiwatana S, Zhang L, Obonyo M. Mechanism of antibacterial activity of liposomal linolenic acid against *Helicobacter pylori*. PLoS One. 2015;**10**(3):e0116519 [59] Li XX, Shi S, Rong L, Feng MQ, Zhong L. The impact of liposomal linolenic acid on gastrointestinal microbiota in mice. International Journal of Nanomedicine. 2018;**13**:1399-1409

[60] Nostro A, Cellini L, Di Bartolomeo S, Di Campli E, Grande R, Cannatelli MA, et al. Antibacterial effect of plant extracts against *Helicobacter pylori*. Phytotherapy Research.

[61] Cowan MM. Plant products as antimicrobial agents. Clinical Microbiology Reviews.

[62] Wu S, Chappell J. Metabolic engineering of natural products in plants; tools of the trade and challenges for the future. Current Opinion in Biotechnology. 2008;**19**(2):145-152

crobial dietary approach. BioMed Research International. 2015;**2015**:11

omega-3 fatty acids. Electronic Physician. 2016;**8**(1):1776-1785

Journal of Gastroenterology. 2013;**19**(47):8986-8995

122 Helicobacter Pylori - New Approaches of an Old Human Microorganism

2014;**111**(49):17600-17605

2006;**7**:467-482

1998;**59**(6):401-406

2005;**19**:198-202

1999;**12**(4):564-582

Medical Journal. 2009;**85**(1000):84-90

*pylori*. Molecular Pharmaceutics. 2012;**9**(9):2677-2685

